Company
Autopoiesis
building AI capable of autonomous scientific discovery
Also known as Autopoiesis Sciences
- Status
- Operatingas of 2026-09-18
- Business model
- B2B
- Headquarters
- San Francisco, United States
- Customers
- thousands of researchers at some of the most demanding institutions in science, including GSK, Pfizer, AstraZeneca, Merck, Stanford, MIT, Harvard, and the FDA
Claim, correct or request removal
Record updated 18 September 2026
About
Reinforcement learning has taken models remarkably far in math and code, where an answer can be checked and a model can learn from ten thousand attempts. Science offers no such reward function. We build the environments and datasets that supply what is missing: expert scientists working on real research problems, and a record of the judgment they exercise before any result is certain. Our long-term goal is a world where discovery is no longer bottlenecked by the number of human scientists alive to pursue it.
Funding snapshot
- Latest round
- Undisclosed2025-07-30
Funding rounds
- Round, 2025
- 2025-07-30
Products
- Other
- Columbus-1
Loading relationship preview